
Does alpha-lactalbumin vaccine lower the risk of triple-negative breast cancer?
Checked
Posts say a vaccine made from the milk protein alpha-lactalbumin can stop triple-negative breast cancer or lower the risk of getting it.
It is not proven that alpha-lactalbumin vaccine lowers the risk of triple-negative breast cancer.
What studies show
As of , no study proves that alpha-lactalbumin vaccine lowers the risk of triple-negative breast cancer. We found 8 published papers on alpha-lactalbumin vaccine and triple-negative breast cancer. They were published between 2017 and 2026. 4 of them are studies in people. None of them was a fair test in which chance decided who got it and who did not. 2 were studies in animals, and none was only in cells in the lab. 1 paper is a review that sums up other studies.
Trials in people
One small early test in people checked safety and the best dose. It enrolled 35 people, some with cancer and some cancer-free but at risk. So far its results are only in the trial record and short meeting reports, not in a full paper.
Other studies in people
Early reports on this test looked at safety and the body's immune reaction. They did not check whether the vaccine stops anyone getting cancer. The serious side effects reported were all reactions at the injection site. 7 of 10 people tested so far showed an immune reaction.
Reviews
A 2020 review suggests vaccinating healthy adults as a way to prevent some cancers. It calls this an idea, not something shown to work.
In animals
In a 2024 study, vaccinated mice had slower tumour growth and lived longer. Results in animals do not always hold in people.
Other papers
A 2026 computer-based paper picked this protein as a vaccine target. It did not test the vaccine in people or animals.
What this means for you
Our verdict: Unproven.
The small tests in people only checked safety and immune reaction. Only mice showed slower tumour growth, and nobody has tested if it prevents cancer in people, so the claim is unproven.
Do not decide anything about alpha-lactalbumin vaccine because of one story or post. A study in people is not proof that it will lower your own risk. If you are thinking about alpha-lactalbumin vaccine to lower your risk of triple-negative breast cancer, ask your doctor first.
This page explains what research has found so far. It is not medical advice. Talk to your doctor before you start, stop or change any treatment.
We searched 18 scientific databases for research from the last 10 years (since 17 Nov 2016).
Sources
- A Multi-Omics Computational Pipeline for Systematic Discovery of Retired Self-Antigens as Cancer Vaccine Targets. medRxiv 2026. Other paper. medRxiv
- Abstract PO2-17-12: Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC. Cancer Research 2024. Study in people. Cancer Research
- 631 Phase I trial of alpha-lactalbumin vaccine in patients with high-risk early triple-negative breast cancer (TNBC) and those at genetic risk for TNBC. Journal for ImmunoTherapy of Cancer 2024. Study in people. Journal for ImmunoTherapy of Cancer
- α-Lactalbumin mRNA-LNP Evokes an Anti-Tumor Effect Combined with Surgery in Triple-Negative Breast Cancer. Pharmaceutics 2024. In animals. PubMed
- Abstract 3035: Phase I trial of alpha-lactalbumin vaccine in high-risk operable triple-negative breast cancer. Cancer Research 2023. Study in people. Cancer Research
- Phase I trial of an alpha-lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC). Journal of Clinical Oncology 2022. Study in people. Journal of Clinical Oncology
- Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. 2021. Study in people. ClinicalTrials.gov
- Primary immunoprevention of adult onset cancers by vaccinating against retired tissue-specific self-proteins. Semin Immunol 2020. Review. PubMed
- Immunotherapeutic target expression on breast tumors can be amplified by hormone receptor antagonism: a novel strategy for enhancing efficacy of targeted immunotherapy. Oncotarget 2017. In animals. PubMed
Frontlight Community
Share what you saw, tried or were told about this claim, and read what others went through. Posts are not medical advice: ask your doctor about your own treatment.
Be the first to share your experience or your question about this claim
You need a Frontlight account with a verified e-mail address to comment.